O'Rourke James, Jiang Xi, Hao Zhifang, Cone Robert E, Hand Arthur R
University of Connecticut Health Center, Farmington, CT 06030-3105, USA.
J Neurosci Res. 2005 Mar 15;79(6):727-33. doi: 10.1002/jnr.20366.
Tissue plasminogen activator (tPA) is the predominant plasminogen activator present in the vascular and nervous systems. Prior studies of the two have emphasized different tPA sources; respectively, endothelium and neurons. A closer relationship is now suggested by evidence that the peripheral sympathetic nervous system synthesizes and infuses enzymatically active tPA into small artery walls and the microcirculation. TPA may thus be the only known neural product able to effect degradation of the artery wall extracellular matrix. This brief review considers historical and current indications for the existence of such an autonomically controlled system and some physiologic implications. Immunohistochemical tPA expression in small arteries and arterioles is more prominent in the outer wall sympathetic axon plexus than in endothelium. Its presence in nerve filaments beneath the seldom-studied adventitia was obscured in earlier localizations. The systemic impact of a neural distribution is suggested by a 60% reduction of blood tPA activity after chemical sympathectomy. TPA-bearing axons extend outward from ganglion neuron cell bodies to reach even thin-walled vasa vasora and uveal microvessels. Ganglion cell bodies synthesize and package tPA in vesicles for the long axoplasmic transport. Densely innervated intact vessels release much greater amounts of tPA in vitro than do larger vessels, indicating a high neuron tPA production capacity and a large storage reservoir available within axon networks. The influence of an autonomically controlled plasmin production within small artery walls on regulation of blood pressure and capillary perfusion awaits further investigation. Its possible role in the pathogenesis of vessel wall matrix degradations in aging, hypertension, and diabetes may also merit further consideration.
组织型纤溶酶原激活剂(tPA)是血管和神经系统中主要的纤溶酶原激活剂。先前对两者的研究强调了不同的tPA来源,分别是内皮细胞和神经元。现在有证据表明,外周交感神经系统合成并将具有酶活性的tPA注入小动脉壁和微循环,这表明它们之间存在更密切的关系。因此,tPA可能是唯一已知的能够影响动脉壁细胞外基质降解的神经产物。这篇简短的综述考虑了这种自主控制系统存在的历史和当前证据以及一些生理意义。小动脉和微动脉中免疫组化tPA的表达在外壁交感神经轴突丛中比在内皮细胞中更明显。在早期定位中,它在很少研究的外膜下神经丝中的存在被掩盖了。化学去交感神经后血液tPA活性降低60%,提示神经分布的全身影响。携带tPA的轴突从神经节神经元细胞体向外延伸,甚至到达薄壁的血管滋养管和脉络膜微血管。神经节细胞体合成并将tPA包装在囊泡中进行长距离轴浆运输。密集支配的完整血管在体外释放的tPA量比大血管多得多,这表明神经元tPA的产生能力很高,轴突网络中有大量的储存库。小动脉壁内自主控制的纤溶酶产生对血压调节和毛细血管灌注的影响有待进一步研究。它在衰老、高血压和糖尿病血管壁基质降解发病机制中的可能作用也值得进一步考虑。